30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC

Key Points

• Emerald Investment Advisers acquired 30,456 TransMedics shares worth approximately $2.02 million, while institutional investors collectively own 99.67% of the company.
• Analyst sentiment is mixed: six analysts rate TMDX a Buy, six rate it Hold, and one rates it Sell. The consensus rating is Hold, with an average price target of $124.18.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast.

Emerald Investment Advisers LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,456 shares of the company's stock, valued at approximately $2,023,000. Emerald Investment Advisers LLC owned approximately 0.09% of TransMedics Group at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Royal Bank of Canada lifted its stake in TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock valued at $1,788,000 after acquiring an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock valued at $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock valued at $34,145,000 after acquiring an additional 86,721 shares during the period. Russell Investments Group Ltd. grew its position in shares of TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company's stock valued at $1,059,000 after acquiring an additional 938 shares during the period. Finally, M&T Bank Corp purchased a new position in shares of TransMedics Group during the 2nd quarter valued at approximately $209,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Piper Sandler restated an "overweight" rating and set a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Weiss Ratings lowered shares of TransMedics Group from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of TransMedics Group from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Needham & Company LLC cut their target price on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group restated a "buy" rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $124.18.

TransMedics Group Stock Up 4.3%

Shares of TMDX opened at $94.77 on Friday. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The stock has a fifty day simple moving average of $77.49 and a two-hundred day simple moving average of $95.32. The company has a market capitalization of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same period in the previous year, the firm posted $0.92 EPS. The company's revenue was up 20.7% compared to the same quarter last year. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1.47 EPS for the current year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company's stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source